Microfluidics guided by deep learning for cancer immunotherapy screening

Author:

Ao Zheng1,Cai Hongwei1,Wu Zhuhao1,Hu Liya1,Nunez Asael1,Zhou Zhuolong23,Liu Hongcheng4,Bondesson Maria1ORCID,Lu Xiongbin23ORCID,Lu Xin35ORCID,Dao Ming6ORCID,Guo Feng13

Affiliation:

1. Department of Intelligent Systems Engineering, Indiana University, Bloomington, IN 47405

2. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202

3. Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202

4. Department of Industrial and Systems Engineering, University of Florida, Gainesville, FL 32611

5. Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556

6. Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139

Abstract

Immunocyte infiltration and cytotoxicity play critical roles in both inflammation and immunotherapy. However, current cancer immunotherapy screening methods overlook the capacity of the T cells to penetrate the tumor stroma, thereby significantly limiting the development of effective treatments for solid tumors. Here, we present an automated high-throughput microfluidic platform for simultaneous tracking of the dynamics of T cell infiltration and cytotoxicity within the 3D tumor cultures with a tunable stromal makeup. By recourse to a clinical tumor-infiltrating lymphocyte (TIL) score analyzer, which is based on a clinical data-driven deep learning method, our platform can evaluate the efficacy of each treatment based on the scoring of T cell infiltration patterns. By screening a drug library using this technology, we identified an epigenetic drug (lysine-specific histone demethylase 1 inhibitor, LSD1i) that effectively promoted T cell tumor infiltration and enhanced treatment efficacy in combination with an immune checkpoint inhibitor (anti-PD1) in vivo. We demonstrated an automated system and strategy for screening immunocyte-solid tumor interactions, enabling the discovery of immuno- and combination therapies.

Funder

HHS | NIH | NIH Office of the Director

HHS | NIH | National Institute on Drug Abuse

HHS | NIH | National Institute of Biomedical Imaging and Bioengineering

HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases

HHS | NIH | National Heart, Lung, and Blood Institute

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3